Loading…
← CockpitCompetitor Analysis › AQST Aquestive Therapeutics, Inc.Open in the cockpit ↗

Aquestive Therapeutics, Inc.AQSTCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 35
Mkt cap
$475M
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$9.32M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.8%
Hurdle
n/a
no reverse DCF
Next earnings
111 days
9 Mar 2027
Close · USD$3.78
1D+2.2%
1W+5.6%
1M-6.7%
3M-15.9%
6M-9.3%
YTD-41.5%
1Y-35.0%
ATR %6.3%
Beta0.88
52w lowhigh43.9% off high

What Aquestive Therapeutics does

Employees: 147

Aquestive Therapeutics at a glance

Size Aquestive Therapeutics (AQST) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $475M, the 2708th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.78 on 18 Nov 2026.

Performance Over six months the shares fell 9.3%, against -14.7% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 12.5% over the last twelve months (peer median +9.4%); the operating margin is -114.1% (peer median 10.7%).

Valuation It trades at 10.9× enterprise value to sales against a peer median of 4.6× (4th most expensive of 19).

Short interest Short interest is 23.3% of the free float (30 Oct 2026).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026AQST 89Peer median 84
Six months, rebased to 100: Aquestive Therapeutics against the median of its 20 peers (local-currency closes).

Aquestive Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$48.8M$44.5M$57.6M$50.6M$47.7M
Revenue growth—-23%+14%+6%—
Gross profit$31.9M$27.4M$39.7M$30.0M$27.8M
EBITDA-$55.2M-$69.1M-$30.1M-$13.5M-$39.7M
Net income-$79.3M-$83.8M-$44.1M-$7.87M-$54.4M
Free cash flow-$40.7M-$53.0M-$35.9M-$7.38M-$10.8M
Capital expenditure$933,000$562,000$159,000$995,000$2.52M
Total debt$150M$131M$122M$98.8M$123M

Quarterly statements and history in the cockpit →

Aquestive Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%SMSPHARMA3705600624301201HNSARGNX6883736620EOLS002370CAPRKPL0026930030203005843012771666AQST6-month return →1-month return →
Up and to the right = strong over both horizons. Aquestive Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%0×10×20×SMSPHARMA3705600624301201HNSARGNX6883736620EOLS002370KPL0026930030203005843012771666ASMBAQSTRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Aquestive Therapeutics is the large dot.

Aquestive Therapeutics competitors and peer comparison

How Aquestive Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aquestive Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureAQSTPeer medianRank in peer set
1-month return-6.7%-2.6%8th lowest of 21
6-month return-9.3%-14.7%10th highest of 20
Distance from 52-week high-43.9%-38.3%8th lowest of 21
Revenue growth (TTM)+12.5%+9.4%10th highest of 20
Operating margin-114.1%10.7%3rd lowest of 19
EV / Sales10.9×4.6×4th most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%10.8×44.1%+1.0%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%2.2×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%

Questions

Which companies are Aquestive Therapeutics's closest peers?
The cockpit's peer set: SMS Pharmaceuticals (SMSPHARMA.NS), YungShin Global (3705.TW), Shanghai Fudan Forward S&T (600624.SS), ChengDa PharmaCeuticals (301201.SZ), Hansa Biopharma (HNSA.ST), REGENXBIO (RGNX), Shanghai MicuRx Pharmaceutical (688373.SS), Handa Pharmaceuticals (6620.TWO).
Is Aquestive Therapeutics expensive compared with its peers?
On ev / sales it trades at 10.9× against a peer median of 4.6×, 4th most expensive of 19 in its peer set.
How has Aquestive Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -9.3% against -14.7% for the median peer; over one year -35.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.